Astrid Botty van Den Bruele

Astrid Botty van Den Bruele

Auto-generated profile, based on publicly available information

Astrid Botty van Den Bruele

Department of Surgery, Duke University, Durham, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HWHannah E. Woriax
Hannah E. Woriax
STSamantha M. Thomas
Samantha M. Thomas
JPJennifer Kay Plichta
Jennifer Kay Plichta
LRLaura H. Rosenberger
Laura H. Rosenberger
ABAstrid Botty van Den Bruele
Astrid Botty van Den Bruele
MDMaggie L. DiNome
Maggie L. DiNome
PURPOSE: Black women have higher rates of death from triple-negative breast cancer (TNBC) than White women. We hypothesized that pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and overall survival (OS) may vary by race/ethnicity in patients with TNBC. METHODS: We identified women 18 years and older with stage I-III TNBC who received NAC followed by surgery from the National Cancer Database (2010-2019). We excluded patients without race/ethnicity or pathology data. Primary outcomes were pCR rates and OS on the basis of race/ethnicity. RESULTS: Forty thousand eight hundred ninety women with TNBC met inclusion criteria (median age [IQR], 53 [44-61] years): 26,150 Non-Hispanic White (64%, NHW), 9,672 Non-Hispanic Black (23.7%, NHB), 3,267 Hispanic (8%), 1,368 Non-Hispanic Asian (3.3%, NHA), and 433 Non-Hispanic Other (1.1%, NHO) patients. Overall, 29.8% demonstrated pCR (NHW: 30.5%, NHB: 27%, Hispanic: 32.6%, NHA: 28.8%, NHO: 29.8%). Unadjusted OS was significantly higher for those with pCR compared with those with residual disease (5-year OS, 0.917 [95% CI, 0.911 to 0.923] v 0.667 [95% CI, 0.661 to 0.673], log-rank P < .001), and this association persisted after adjustment for demographic and tumor factors. The effect of achieving pCR on OS did not differ by race/ethnicity (interaction P = .10). However, NHB patients were less likely (odds ratio [OR], 0.89 [95% CI, 0.83 to 0.95], P = .001) and Hispanic patients were more likely (OR, 1.19 [95% CI, 1.08 to 1.31], P = .001) to achieve pCR than NHW patients. After adjustment for patient and disease factors, including achievement of pCR, Hispanic (hazard ratio [HR], 0.76 [95% CI, 0.69 to 0.85], P < .001) and NHA (HR, 0.64 [95% CI, 0.55 to 0.75], P < .001) race/ethnicity remained associated with OS. CONCLUSION: Odds of achieving pCR and OS in patients with TNBC appear to be associated with race/ethnicity. Additional research is necessary to understand how race/ethnicity is associated with rates of pCR and OS, whether related to socioeconomic factors or biologic variables, or both.

1 November 2018 in Journal of Surgical Research
Verified
Journal Article
Closed access
ABAstrid Botty Van Den Bruele
Astrid Botty Van Den Bruele
BJBharti Jasra
Bharti Jasra
CSCarmen Smotherman
Carmen Smotherman
MCMarie Crandall
Marie Crandall
LSLaila Samiian
Laila Samiian

13 January 2025 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
ABAstrid Botty van Den Bruele
Astrid Botty van Den Bruele
AWAustin Williams
Austin Williams
AWAnna Weiss
Anna Weiss
CGCollaborators from the Society of Surgical Oncology Breast Disease Site Work Group
Collaborators from the Society of Surgical Oncology Breast Disease Site Work Group
OFOluwadamilola M. Fayanju
Oluwadamilola M. Fayanju
FDFrederick M. Dirbas
Frederick M. Dirbas

5 July 2024 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
ABAstrid Botty van Den Bruele
Astrid Botty van Den Bruele
AWAnna Weiss
Anna Weiss

27 February 2025 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ABAstrid Botty van Den Bruele
Astrid Botty van Den Bruele
YRYi Ren
Yi Ren
STSamantha M. Thomas
Samantha M. Thomas
KNKoumani W. Ntowe
Koumani W. Ntowe
LRLaura H. Rosenberger
Laura H. Rosenberger
JPJennifer K. Plichta
Jennifer K. Plichta

1 March 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
TWTon Wang
Ton Wang
DNDrew Neish
Drew Neish
STSamantha M Thomas
Samantha M Thomas
ABAstrid Botty van Den Bruele
Astrid Botty van Den Bruele
LRLaura H. Rosenberger
Laura H. Rosenberger
JPJennifer Kay Plichta
Jennifer Kay Plichta
PURPOSE: Guidelines recommend omission of sentinel lymph node biopsy (SLNB) for axillary staging in select patients age 70 years and older with early-stage estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 neu–negative (HER2–) invasive breast cancers (BCs). However, many women meeting criteria for SLNB omission continue to receive this procedure. This study aims to stratify patients into risk cohorts for nodal positivity that can be incorporated into deimplementation strategies to reduce low-value SLNB procedures. METHODS: A retrospective cohort analysis using the National Cancer Database was performed on patients age 70 years and older with ER+/HER2–, cT1-2, cN0, cM0 BC who underwent breast surgery from 2018 to 2021. Patients who received neoadjuvant therapies were excluded. Recursive partitioning analysis (RPA) was used to develop two models to estimate nodal positivity: (1) a clinical model for preoperative use to decide whether to perform SLNB and (2) a pathologic model for postoperative use to guide adjuvant decisions in cases of SLNB omission. RESULTS: The study included 68,867 patients who received SLNB; 13.4% had a tumor-involved lymph node. RPA on the basis of clinical covariates demonstrated <8% risk of nodal positivity for patients with cT1mi-cT1b and grade 1-2 tumors. RPA on the basis of pathologic covariates found <10% risk of nodal positivity for patients with pT1 tumors without lymphovascular invasion (LVI). Patients with cT2 or pT2 without LVI and nonductal/nonlobular histology had <5% risk of nodal positivity. CONCLUSION: This study demonstrates a low risk of nodal positivity for patients with cT1 or pT1 tumors. Our RPA-defined subgroups offer a novel approach to predict nodal positivity in patients age 70 years and older with early-stage, ER+/HER2– invasive BC that can be incorporated in deimplementation strategies to reduce low-value axillary surgery.